A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
Abroad (travel likely)RecruitingPHASE2
Conditions
Malaria
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
GSK Investigational Site, Kigali, Rwanda
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Julien Nyombayire)GSK Investigational Site, Kigali, Rwanda
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Mossi Nzeyimana)
Study leads
Julien M Nyombayire, MD, MSc
Principal Investigator
Center for Family Health Research
Mossi Nzeyimana, MD
Principal Investigator
Rinda Ubuzima Gatenga Medicalized Health Center University of Rwanda